SUBJECTS AND METHODS

Eighty
six women with the unidentified complaints who showed no sign of either gynecological or any other somatic diseases were subjected to this study.
First, they were requested to fill a questionnaire (Table 1) containing 11 items concern ing various kinds of symptoms, and on the basis of which Kupperman's menopausal index (Kupperman et al. 1959 ) was calculated.
Then, the patients were given an intravenous injection of 20 mg of conjugated estrogen (Premarin) and the menopausal index was calculated again at 3 or 4 days after injection.
Subsequently, they were entrusted to psychiatrists to determine the presence or absence of psychiatric abnormalities. They were divided into two groups, one with and the other without psychiatric abnormalities, accord ing to the diagnosis by the psychiatrists.
A comparison was made between the two groups with respect to the effect of conjugated estrogen on the menopausal index. Secondly, the conjugated estrogen or placebo was injected intravenously into the women without psychiatric abnormalities in order to evaluate the effect of conjugated estrogen on the unidentified complaints by the double blind test, comparing menopausal indices before and after injection. (Kupperman 1959) .
EXPERIMENTAL RESULTS
Of 86 women 17 were with psychiatric abnormalities and 69 without them . There was no significant difference in age between the two groups of the patients , as shown in Table 2 . Psychiatric abnormalities included neurosis in 16 cases (94 %) and schizophrenia in 1 case (6%). showed a decrease of the menopausal index after intravenous injection of conjugat ed estrogen, while most of the abnormal group showed little change. This difference in the reaction to the conjugated estrogen between the two groups was proved to be significant by the t-test (p<0.01) ( Table 3) . With Kupperman's menopausal indices determined before and after admin istration of conjugated estrogen, expressed as variables X0 and X1, respectively, a discriminant function between the two groups was calculated by the following formula:
The values of X0 and Xl of each woman were applied to this formula. When Y was positive, she was classified into the normal group ; when negative, she was classified into the abnormal group. This calculative diagnosis was consistent with the clinical one in about 88.2% of the cases of the abnormal group and about 75.4% of the cases of the normal group. In the next experiment, the patients without psychiatric abnormalities were
given an intravenous injection of conjugated estrogen or placebo by the double blind method, in order to confirm the effect on the menopausal index. Fig. 2 shows the menopausal indices before and after intravenous injection: those before injection on the abscissa and those after injection on the ordinate. the menopausal index before intravenous injection less than 20, and the other showed the index of 20 or more. In the latter group, significant decreases of the index were observed after administration of conjugated estrogen (p<0.05 by t-test); while, in the former group, the conjugated estrogen did not exert any significant effect.
DISCUSSION
Although the basic treatment for the pre-, mid-and post-menopausal unidentified complaints has been thought to include hormonal therapy and psychotherapy (Dilts et al. 1971; Kistner 1972 ), indication of these therapies is not always clear at the moment. Only some, not all, of women complaining of the unidentified complaints seem to need psychotherapy. The presence or absence of psychiatric disorders is important for the choice of treatments because psychiatric treatments such as psychotherapy, rather than hormonal therapy, have to be primarily applied to the cases of women with psychiatric disorders. On etiology of the menopausal symptoms, it has been said (titian 1972; Aitken et al. 1974 ) that the only symptom directly associated with the menopause is hot flushes and that other symptoms, such as depression, irritability, angina pectoris, insomnia and palpitation, are most likely of psychological origin. In the present study, the conjugated estrogen was proved, by the double blind test, to be strongly suggestive of exerting some specific effect for relief of the unidentified complaints of the pre-, mid-and post-menopausal women. However, since the physiological mechanism of the onset of menopausal symptom in relation to estrogen secretion has not yet been established at the moment, the significance of the decrease of Kupperman's menopausal index after intravenous injection of conjugated estrogen found in the cases of psychiatrically normal group should be studied in more detail in future.
From the results of clinical evaluation of the author's new method for the screening of psychiatrically abnormal women (tentatively designated as 'Premarin test'), it was found that women diagnosed as having psychiatric disorders by the psychiatrist were screened by this method with about 88.2% accuracy. This suggests that the test is useful in actual clinical practice as a method for the screening of psychiatrically disordered cases among pre-, mid-and post menopausal women with unidentified complaints syndrome.
